These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38962544)

  • 1. Efficacy of Magnesium Supplementation in Cancer Patients Developing Hypomagnesemia Due to Anti-EGFR Antibody: A Systematic Review.
    Kato T; Kawaguchi T; Funakoshi T; Fujiwara Y; Yasuda Y; Ando Y
    Cancer Diagn Progn; 2024; 4(4):390-395. PubMed ID: 38962544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporary loss of consciousness during cetuximab treatment of a patient with metastatic colon cancer: a case report.
    Fukui T; Suzuki K; Tamaki S; Abe I; Endo Y; Ishikawa H; Kakizawa N; Watanabe F; Saito M; Tsujinaka S; Futsuhara K; Miyakura Y; Noda H; Rikiyama T
    Surg Case Rep; 2019 Oct; 5(1):145. PubMed ID: 31637554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Epidermal Growth Factor Receptor Inhibitor-Induced Hypomagnesemia: A Systematic Review.
    Jiang DM; Dennis K; Steinmetz A; Clemons M; Asmis TR; Goodwin RA; Vickers MM
    Clin Colorectal Cancer; 2016 Sep; 15(3):e117-23. PubMed ID: 26961757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between blood magnesium and calcium concentration in patients treated with an anti-EGFR antibody.
    Tsujii T; Ogaki T; Nakae K; Imai K; Kise D; Tada S; Ueda H; Moriyama M
    J Pharm Health Care Sci; 2016; 2():23. PubMed ID: 27688901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of magnesium supplementation on early-stage hypomagnesemia in patients treated with cetuximab].
    Demizu M; Ueda H; Osawa M; Chihara S; Igarashi T; Yano K; Kimura F; Tanaka N; Hiratsuka M
    Gan To Kagaku Ryoho; 2013 Jul; 40(7):897-900. PubMed ID: 23863731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer.
    Fujii H; Iihara H; Suzuki A; Kobayashi R; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1209-15. PubMed ID: 27106835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies.
    Petrelli F; Borgonovo K; Cabiddu M; Ghilardi M; Barni S
    Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S9-19. PubMed ID: 21843103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying optimal magnesium replenishment points based on risk of severe hypomagnesemia in colorectal cancer patients treated with cetuximab or panitumumab.
    Kimura M; Usami E; Teramachi H; Yoshimura T
    Cancer Chemother Pharmacol; 2020 Sep; 86(3):383-391. PubMed ID: 32789758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relationship between the Incidence of Hypomagnesemia and Acneiform Rash and the Therapeutic Effect of Anti-EGFR Monoclonal Antibody in Patients with Metastatic Colorectal Cancer].
    Fujii H; Iihara H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
    Gan To Kagaku Ryoho; 2016 Feb; 43(2):229-33. PubMed ID: 27067688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study.
    Schulz C; Heinemann V; Heinrich K; Haas M; Holch JW; Fraccaroli A; Held S; von Einem JC; Modest DP; Fischer von Weikersthal L; Kullmann F; Moehler M; Scheithauer W; Jung A; Stintzing S
    Anticancer Drugs; 2020 Sep; 31(8):856-865. PubMed ID: 32639280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab-induced hypomagnesemia in patients with colorectal cancer.
    Fakih MG; Wilding G; Lombardo J
    Clin Colorectal Cancer; 2006 Jul; 6(2):152-6. PubMed ID: 16945172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnesium monitoring practice in monoclonal anti-epidermal growth factor receptor antibodies therapy.
    do Pazo-Oubiña F; Estefanell-Tejero A; Riu-Viladoms G; Anglada-Martínez H; Molas-Ferrer G; Creus-Baró N
    J Clin Pharm Ther; 2013 Apr; 38(2):101-3. PubMed ID: 23278401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta-analysis.
    Chen P; Wang L; Li H; Liu B; Zou Z
    Oncol Lett; 2013 Jun; 5(6):1915-1920. PubMed ID: 23833666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of incidence and risk of hypomagnesemia with cetuximab for advanced cancer.
    Cao Y; Liao C; Tan A; Liu L; Gao F
    Chemotherapy; 2010; 56(6):459-65. PubMed ID: 21088398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
    Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
    Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of frequency and severity of hypomagnesemia in patients with metastatic colorectal cancer treated with cetuximab, with a review of the literature.
    Streb J; Püsküllüoğlu M; Glanowska I; Ochenduszko S; Konopka K; Łupkowski R; Michalowska-Kaczmarczyk A; Bochenek-Cibor J; Majka M; Krzemieniecki K
    Oncol Lett; 2015 Dec; 10(6):3749-3755. PubMed ID: 26788202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis.
    Hsieh MC; Wu CF; Chen CW; Shi CS; Huang WS; Kuan FC
    Sci Rep; 2018 Feb; 8(1):2047. PubMed ID: 29391418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials.
    Wang Q; Qi Y; Zhang D; Gong C; Yao A; Xiao Y; Yang J; Zhou F; Zhou Y
    Tumour Biol; 2015 May; 36(5):3471-82. PubMed ID: 25542231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.